Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)
In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), ...